389 related articles for article (PubMed ID: 24262196)
21. [Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].
Wakabayashi K
Rinsho Shinkeigaku; 2008 Nov; 48(11):981-3. PubMed ID: 19198138
[TBL] [Abstract][Full Text] [Related]
22. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
24. TIGAR inclusion pathology is specific for Lewy body diseases.
López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
[TBL] [Abstract][Full Text] [Related]
25. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
26. Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinson's Disease and Multiple System Atrophy.
Sonustun B; Altay MF; Strand C; Ebanks K; Hondhamuni G; Warner TT; Lashuel HA; Bandopadhyay R
Cells; 2022 Mar; 11(5):. PubMed ID: 35269528
[TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
28. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.
Picca A; Guerra F; Calvani R; Romano R; Coelho-Júnior HJ; Bucci C; Marzetti E
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680141
[TBL] [Abstract][Full Text] [Related]
30. [The mechanism of Lewy body formation in Parkinson's disease].
Wakabayashi K; Takahashi H
Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
[TBL] [Abstract][Full Text] [Related]
31. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Spillantini MG; Goedert M
Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
[TBL] [Abstract][Full Text] [Related]
32. More than meets the eye in Parkinson's disease and other synucleinopathies: from proteinopathy to lipidopathy.
Flores-Leon M; Outeiro TF
Acta Neuropathol; 2023 Sep; 146(3):369-385. PubMed ID: 37421475
[TBL] [Abstract][Full Text] [Related]
33. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
34. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease.
Negi S; Khurana N; Duggal N
Neurochem Int; 2024 Jul; 177():105760. PubMed ID: 38723900
[TBL] [Abstract][Full Text] [Related]
35. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
[TBL] [Abstract][Full Text] [Related]
36. TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains.
Zucchelli S; Codrich M; Marcuzzi F; Pinto M; Vilotti S; Biagioli M; Ferrer I; Gustincich S
Hum Mol Genet; 2010 Oct; 19(19):3759-70. PubMed ID: 20634198
[TBL] [Abstract][Full Text] [Related]
37. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
[TBL] [Abstract][Full Text] [Related]
38. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
[TBL] [Abstract][Full Text] [Related]
39. [The role of alpha-synuclein in Parkinson's disease].
Miklya I; Pencz N; Hafenscher F; Göltl P
Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
[TBL] [Abstract][Full Text] [Related]
40. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
Braak H; Sandmann-Keil D; Gai W; Braak E
Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
